Fig. 4

Correlation between SEMA3C and GEM-resistance in PDAC cells and patient samples. (A) LDH cytotoxicity assay of GEM comparing BxPC-3 cells transfected with control siRNA, SEMA3C siRNA1, and SEMA3C siRNA2. (B, C) IHC analysis of SEMA3C expression in locally advanced human PDAC samples. Kaplan–Meier analyses of locally advanced PDAC patients with high vs. low SEMA3C expression for overall survival in the NAC group (high SEMA3C group; MST 22.7 months, low SEMA3C group; MST 44.1 months, p = 0.02) (B), and in the upfront surgery group (high SEMA3C group; MST 15.5 months, low SEMA3C group; MST 28.7 months, p = 0.33) (C). The protein expression of c-Met, Akt, mTOR, and their phosphorylation using Western blot analysis in BxPC3 (D, left panel) and MIA-PaCa-2 cells (E, left panel). The expression of p-Met relative to c-Met and p-mTOR relative to mTOR in BxPC-3 cells (D, right panel) and MIA PaCa-2 cells (E, right panel)